share_log

Morgan Stanley Maintains Equal-Weight on Senti Biosciences, Lowers Price Target to $3

Morgan Stanley Maintains Equal-Weight on Senti Biosciences, Lowers Price Target to $3

摩根士丹利维持对Senti Biosciences的同等权重,将目标价下调至3美元
Benzinga Real-time News ·  2023/01/27 10:35

Morgan Stanley analyst Michael Ulz maintains Senti Biosciences (NASDAQ:SNTI) with a Equal-Weight and lowers the price target from $7.5 to $3.

摩根士丹利分析师迈克尔·乌尔茨维持森蒂生物科学公司(纳斯达克:SNTI)的同等权重,并将目标价从7.5美元下调至3美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发